Table 3.

Comparison of overall response rates to anti-PD-1 and anti-PD-L1 therapy based on histology and PD-L1 IHC expression

Therapeutic agentDetection antibody; membrane staining cutoff (in percent of tumor cells)HistologyPD-L1 IHC expression (% samples at IHC level)Response rate for PD-L1–positive versus PD-L1–negative patientsPFS for PD-L1–positive versus PD-L1–negative patientsOS for PD-L1–positive versus PD-L1–negative patientsRef(s)
Nivolumab28-8; 5%Melanoma (n = 38)+ (45%) − (55%)44% vs. 17% (P = NR)9.1 vs. 2 months (median PFS, P = NR)21.1 vs. 12.5 months (median OS, P = NR)(76)
DAKO; 5%NSCLC (n = 20)+ (60%)− (40%)67% vs. 0% (P = NR)NRNR(71)
5H1; 5%Melanoma, RCC, NSCLC, CRC, prostate+ (60%)− (40%)36% vs. 0% (P = NR)NRNR(4)
PembrolizumabNR; 1%Melanoma (n = 71)+ (77%)− (23%)51% vs. 6% (P = 0.0012)12 vs. 3 months (median PFS; P = 0.0004)84% vs. 69% (1- year OS rate; P = 0.2146)(70)
NR; 50%NSCLC (n = 38)+ (25%)− (75%)67% vs. 0% (6-month irORR; P < 0.001)67% vs. 11% (6-month PFS rate; P = 0.009)89% vs. 33% (6-month OS rate; P = NR)(49)
MPDL3280ARoche/GenentechNSCLC, RCC, melanoma, CRC, gastric cancerNR39% vs. 13% (P = NR)NRNR(26, 73)
Roche/GenentechNSCLC (n = 37)+ (13%)− (87%)100% vs. 15% (P = NR)NRNR(72)
Roche/GenentechBladder (n = 20)NR52% vs. 11% (P = NR)NRNR(25)

Abbreviations: CRC, colorectal cancer; NR, not reported.